Advertisement

Topics

iStent inject with phaco yields clinically significant IOP reduction

10:00 EDT 16 Apr 2018 | Healio

Thomas w. Samuelson
WASHINGTON — Patients who received an iStent inject with phacoemulsification experienced clinically significant reductions in unmedicated diurnal IOP compared with patients who underwent phacoemulsification alone, according to 24-month study results.
The prospective, randomized, controlled trial included 387 patients with mild to moderate open-angle glaucoma who received the iStent inject (Glaukos) and underwent phacoemulsification and 118 patients who underwent phacoemulsification alone.
According to a company press release, “The iStent inject is designed to

Original Article: iStent inject with phaco yields clinically significant IOP reduction

NEXT ARTICLE

More From BioPortfolio on "iStent inject with phaco yields clinically significant IOP reduction"

Advertisement
Quick Search
Advertisement
Advertisement